Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutant Non-Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableLooking for participantsNCT07806604
What this trial is testing

Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Betta Pharmaceuticals Co., Ltd. 2,572
Testing effectiveness (Phase 2)Ended earlyNCT04099836
What this trial is testing

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Who this might be right for
Non Small Cell Lung Cancer
Duke University 7
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06688656
What this trial is testing

Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant NSCLC

Who this might be right for
Lung Cancer
Shanghai Chest Hospital 30
Testing effectiveness (Phase 2)Study completedNCT03256136
What this trial is testing

Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC

Who this might be right for
Lung Cancer
Massachusetts General Hospital 9
Early research (Phase 1)Active Not RecruitingNCT03333343
What this trial is testing

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Who this might be right for
EGFR-mutant Non-small Cell Lung Cancer
Novartis Pharmaceuticals 105
Testing effectiveness (Phase 2)WithdrawnNCT02297425
What this trial is testing

Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Who this might be right for
Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer
Testing effectiveness (Phase 2)Looking for participantsNCT07518160
What this trial is testing

JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study

Who this might be right for
Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations
Shanghai Junshi Bioscience Co., Ltd. 35
Testing effectiveness (Phase 2)Study completedNCT03623750
What this trial is testing

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Instituto Oncológico Dr Rosell 23
Testing effectiveness (Phase 2)Looking for participantsNCT07323056
What this trial is testing

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Who this might be right for
EGFR-mutant Non-small Cell Lung CancerPotentially Resectable
Shanghai Pulmonary Hospital, Shanghai, China 36
Not applicableLooking for participantsNCT07837739
What this trial is testing

Adjuvant EGFR-TKI Therapy After Surgery for EGFR-Mutant High-Risk Stage IA2-IIB NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Tongji Hospital 100
Not applicableUnknownNCT04944069
What this trial is testing

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

Who this might be right for
NSCLCLeptomeningeal MetastasisEGFR Activating Mutation
Second Affiliated Hospital of Nanchang University 69
Early research (Phase 1)Study completedNCT02789345
What this trial is testing

Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Eli Lilly and Company 29
Testing effectiveness (Phase 2)Ended earlyNCT03091491
What this trial is testing

Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
National Cancer Centre, Singapore 31
Testing effectiveness (Phase 2)UnknownNCT05498389
What this trial is testing

EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8+6 more
Shanghai EpimAb Biotherapeutics Co., Ltd. 115
Testing effectiveness (Phase 2)UnknownNCT04148898
What this trial is testing

Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis

Who this might be right for
Leptomeningeal MetastasisNon-small Cell Lung CancerEGFR Activating Mutation
Second Affiliated Hospital of Nanchang University 80
Testing effectiveness (Phase 2)UnknownNCT04636593
What this trial is testing

Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC

Who this might be right for
Non Small Cell Lung CancerStage III NSCLCEGFR Activating Mutation
First People's Hospital of Hangzhou 43
Testing effectiveness (Phase 2)WithdrawnNCT02705339
What this trial is testing

Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell LungNon-Small Cell Lung CancerNonsmall Cell Lung Cancer
Washington University School of Medicine
Testing effectiveness (Phase 2)UnknownNCT05007938
What this trial is testing

Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 30
Not applicableWithdrawnNCT05116618
What this trial is testing

Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and ROS1-rearranged

Who this might be right for
Non-Small Cell Lung Cancer
University of Colorado, Denver
Large-scale testing (Phase 3)Not Yet RecruitingNCT07376382
What this trial is testing

A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC

Who this might be right for
NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 680
Next Page